

Company Number 6675642  
Charity Registration Number 1127495

**BARRETT'S OESOPHAGUS CAMPAIGN**

**REPORT AND ACCOUNTS**

**FOR THE PERIOD ENDED 30 SEPTEMBER 2009**

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **CONTENTS**

---

	<b>Page</b>
<b>LEGAL AND ADMINISTRATIVE INFORMATION</b>	<b>1</b>
<b>DIRECTORS' AND TRUSTEES' REPORT</b>	<b>3</b>
<b>STATEMENT OF FINANCIAL ACTIVITIES</b>	<b>7</b>
<b>BALANCE SHEET</b>	<b>8</b>
<b>NOTES TO THE ACCOUNTS</b>	<b>9</b>
<b>PRESENTATIONS AND PUBLICATIONS (UKBOR)</b>	<b>15</b>

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **LEGAL AND ADMINISTRATIVE INFORMATION**

### **Vice-Presidents**

Earl Attlee  
Professor Ian Gilmore MD FRCP  
Mr. Bernard Ribeiro CBE PRCS  
Professor Dame Carol Black DBE MD FRCP  
The Rt Hon David Blunkett MP  
Sir Barry Jackson MS FRCS FRCP  
Professor A I Morris MSc MD FRCP  
Martyn Lewis CBE  
Lord Turnberg of Cheadle MD FRCP FmedSci  
Professor Anthony Watson MD FRCS(Engl)  
FRCS(Ed) FRACS  
Professor Robin Williamson FRCS

### **Trustee Directors**

Dr RC Fitzgerald MA MD FRCP  
Mr. C V Marchant-White  
Dr P R Salmon – Chairman BSc (Hons) MB  
MRCS(Engl) FRCP(Lond) FRCP(Ed)  
Dr P I Reed MB FRCP FRCPC  
Mr. H A Hyman MA FCA MCT  
Mrs. M McCord  
Mr. T Thornton-Jones  
Belinda Johnston BSc

### **Principal office**

UK National Barrett's Oesophagus Registry  
UCL, Division of Surgery and Interventional  
Science  
Royal Free Campus  
Royal Free and University College Medical  
School  
Rowland Hill Street  
London NW3 2PF  
Telephone: 020 7472 6223  
Facsimile: 020 7471 6224

### **Registrar**

Dr C P J Caygill BSc PhD

### **Charity registration number**

1127495

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **LEGAL AND ADMINISTRATIVE INFORMATION (CONTINUED)**

### **Reporting accountants**

Sedley Richard Laurence Voulters  
1 Conduit Street  
London W1S 2XA

### **Bankers**

Coutts & Co  
440 Strand  
London WC1R 0QS

### **Solicitors**

Lawrence Graham LLP  
4 More London Riverside  
London SE1 2AU

### **Company Secretary**

Nexus Management Services Limited  
2<sup>nd</sup> Floor, Griffin House  
West Street  
Woking  
Surrey GU21 6BS  
Telephone: 01483 749020  
Facsimile: 01483 749021

### **Company registered office**

4 More London Riverside  
London SE1 2AU

# BARRETT'S OESOPHAGUS CAMPAIGN

## DIRECTORS' AND TRUSTEES' REPORT

**For the period ended 30 September 2009**

The directors present their report and accounts for the period from 18 August 2008, the date of incorporation of the company, to 30 September 2009.

The directors have adopted the relevant provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" issued in October 2005 in preparing their report and accounts for the period.

The 2008 comparative figures provided in this report and shown in the accounts are from the Barrett's Oesophagus Foundation report and accounts for the year ended 30 September 2008 and have been included for comparative purposes only.

### Reference and administrative details

Reference and administrative details are shown on pages 1 to 2 of this report and accounts.

### Structure, governance and management

The charity was incorporated on 18 August 2008 as a company limited by guarantee and is governed by its memorandum and articles of association dated on that date.

The directors, who are also trustees of the charity, who served during the period, were:

	<b>Date of appointment</b>	<b>Date of resignation</b>
Dr P R Salmon (Chairman)	03.12.2008	
Dr RC Fitzgerald	03.12.2008	
Mr. H A Hyman	03.12.2008	
Mr C V Marchant-White	03.12.2008	09.02.2010
Mrs. M McCord	03.12.2008	09.02.2010
Dr P I Reed	03.12.2008	
Mr. T Thornton-Jones	03.12.2008	
Belinda Johnston BSc	01.01.2009	

Trustees will serve a three-year term deemed to run from the beginning of the calendar year in which they were appointed and conclude at the first board meeting held after their third anniversary as trustees.

None of the directors has any beneficial interest in the company. All of the directors are members of the company and have guaranteed to contribute £1 each in the event of a winding up.

The charity ensures that the trustees are fully aware of their duties and responsibilities which are discussed at the regular meetings of the board.

### Risk management

The directors have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks. The board will continually monitor the risks to which the charity is exposed and implement procedures to minimise the potential impact of those risks.

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **DIRECTORS' AND TRUSTEES' REPORT (continued)**

**For the period ended 30 September 2009**

### **Objectives and activities**

The Barrett's Oesophagus Campaign is the only charity whose main objective is related to prevention of oesophageal cancer.

'Barrett's oesophagus' is a pre-cancerous condition of the oesophagus (gullet) arising as a consequence of prolonged regurgitation (reflux) of acid and bile from the stomach into the oesophagus, the lining of which in consequence alters its characteristics which in a proportion of sufferers can undergo malignant change and lead to the development of a type of cancer of the oesophagus (adenocarcinoma) with a relatively poor outlook. The incidence of both Barrett's oesophagus and adenocarcinoma of the oesophagus and gastric cardia is increasing in many countries including the United Kingdom.

Because the natural history of Barrett's oesophagus and of its most important complication, adenocarcinoma of the oesophagus, is still not clearly understood, much more data are required to formulate the best way of treating Barrett's oesophagus and preventing adenocarcinoma.

The United Kingdom National Barrett's Oesophagus Registry (UKBOR) was started in 1996 with a very generous donation from a non-medical charity supplemented by other contributions from charities and patients with Barrett's oesophagus. UKBOR now has the largest database of Barrett's oesophagus patients in the world with over 10,000 patients from 43 centres. The results of its research have been published and presented nationally and internationally and several European countries plan to develop national registries based on the UK model.

The Barrett's Oesophagus Campaign exists to

- Secure the long-term future of UKBOR
- Provide a support and education service for patients and relatives of patients with Barrett's oesophagus and associated adenocarcinoma of the oesophagus and gastric cardia;
- Make research awards and project grants for research in the field of Barrett's oesophagus in the United Kingdom.

### **Achievements and performance**

As mentioned in the report and accounts of The Barrett's Oesophagus Foundation for the year ended 30 September 2008, the charity has been undergoing a period of change to improve its image, raise awareness and develop relations with the press and the public. The 3<sup>rd</sup> Sector PR ("TSPR"), a public relations company specialising in charities, was appointed to assist with this endeavour to re-brand the charity which commenced with the change of the charity's name to "Barrett's Oesophagus Campaign" and the introduction of the "Patient Support Network" to replace the confusing name "PROBE" for the patient support group. A small working group which met every 6 to 8 weeks was set up to work with a team of professionals (graphic designers, website designers and medical editor) recruited by TSPR to completely redesign the charity's website and leaflets. The charity's new image was launched on 26 February 2009 at a meeting at University College, London, and the charity's website ([www.barrettscampaign.org.uk](http://www.barrettscampaign.org.uk)) was relaunched on 15 May 2009. The directors are pleased with the results of the re-branding of the charity although it meant that the charity had to incur costs which resulted in a higher level of resources expended during the period compared with that for the year ended 30 September 2008.

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **DIRECTORS' AND TRUSTEES' REPORT (continued)**

### **For the period ended 30 September 2009**

The directors are also pleased to note that in spite of the time-consuming effort they had expended in the re-branding exercise during the year, there has not been a decline in the level of donations received during the period compared with 2008 and look to the future with confidence.

#### **Financial review and reserves policy**

During the period, incoming resources of the charity, including resources of £161,589 transferred from The Barrett's Oesophagus Foundation to the company, amounted to £196,901. From this total resources expended during the period of £112,868 (2008: £73,553) were deducted, resulting in net incoming resources of £84,033 (2008: £48,867) for the period which were carried forward.

Except for such funds as the trustees consider prudent to maintain for the purposes of management and administration of the charity for the foreseeable future, all unrestricted funds are for the purposes of the general charitable objects of the charity. Such free unrestricted funds at 30 September 2009 amounted to £19,144 (2008: £94,556).

#### **Post balance sheet events**

A successful fundraising event was held at Vintners Hall, London, on 5 October 2009.

During February 2010 a demerger of the McCord Oesophageal Cancer Fund was agreed by all trustee/directors in the interests of the charity and a demerger timetable was subsequently agreed. Negotiations are currently taking place during May 2010 regarding the division of assets, to be followed by completion as soon as possible.

#### **Statement of directors' and trustees' responsibilities**

The trustees are also directors of the company for the purposes of the Companies Act 2006.

Company law and charity legislation require the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors have regard to the Statement of Recommended Practice on 'Accounting and Reporting by Charities' issued by the Charity Commission; they are also required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any departures disclosed and explained in the accounts; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

In accordance with company and charity legislation, the directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company which enable them to ensure that the financial statements comply with the Companies Act 2006

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **DIRECTORS' AND TRUSTEES' REPORT (continued)**

**For the period ended 30 September 2009**

and the Charities Act 1993. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The directors as trustees are responsible for ensuring that the Trustees' Report is prepared in accordance with charity law in the United Kingdom.

The directors are responsible for the maintenance and integrity of the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

### **Small company provisions**

These accounts have been prepared in accordance with the provisions in the Companies Act 2006 applicable to companies subject to the small companies' regime.

### **Audit exemption and reporting accountants**

The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. An external independent scrutiny of these accounts was considered unnecessary in the interest of the conservation of the charity's funds. Accordingly the reporting accountants Sedley Richard Laurence Voulters have not carried a review of these accounts and consequently an Accountants' Report has not been included in this report and accounts. Sedley Richard Laurence Voulters have indicated their willingness to continue in office for the ensuing year.

Approved by the board of directors on 14 May 2010 and signed on its behalf:



For and on behalf of  
Nexus Management Services Limited  
Secretary



# BARRETT'S OESOPHAGUS CAMPAIGN

## STATEMENT OF FINANCIAL ACTIVITIES

For the period ended 30 September 2009

		General Funds £	Restricted Funds £	Period ended 30.09.2009 Total £	Year ended 30.09.2008 (See note below) £
<b>Income and expenditure</b>	Notes				
<b>Incoming resources</b>					
Donations received	2	7,102	27,615	34,717	27,555
Proceeds of fundraising activities		-	-	-	-
Bank interest receivable		321	-	321	3,233
Gift aid reclaimed		244	-	244	1,639
PROBE Membership fees		-	30	30	361
Sales	3	-	-	-	15
Sub total		<u>7,667</u>	<u>27,645</u>	<u>35,312</u>	<u>32,803</u>
Transfers from:					
- The Barrett's Oesophagus Foundation		97,756	63,833	161,589	-
- McCord Oesophageal Cancer Fund		-	-	-	89,617
<b>Total incoming resources</b>		<u>105,423</u>	<u>91,478</u>	<u>196,901</u>	<u>122,420</u>
<b>Resources expended</b>					
Cost of generating funds					
- Fundraising consultancy		-	1,714	1,714	6,726
- Fundraising activities		-	-	-	-
Charitable activities					
- CAF and Just giving charges		156	-	156	70
- Grants and awards	5	-	20,000	20,000	141
- Registry		-	21,345	21,345	23,546
- Patient information and website		-	6,519	6,519	4,424
- Conferences		3,631	-	3,631	2,185
- Research		-	-	-	634
- Maintenance of endoscopy equipment		-	7,708	7,708	-
- Depreciation of endoscopy equipment		-	9,000	9,000	9,000
Governance costs					
- Office & administration costs		2,328	-	2,328	424
- Directors / Trustees administrative costs		347	-	347	370
- Public Relations consultancy		29,253	-	29,253	-
- Legal and professional fees		10,781	-	10,781	22,277
- Accounting		86	-	86	2,875
- Reporting accountants / audit fees		-	-	-	881
<b>Total resources expended</b>		<u>46,582</u>	<u>66,286</u>	<u>112,868</u>	<u>73,553</u>
Net incoming (outgoing) resources	4	58,841	25,192	84,033	48,867
Brought forward		-	-	-	112,722
Transfers from the General Fund		<u>(39,697)</u>	<u>39,697</u>	<u>-</u>	<u>-</u>
Carried forward		<u>19,144</u>	<u>64,889</u>	<u>84,033</u>	<u>161,589</u>

All amounts relate to continuing activities.

There were no gains or losses other than the result for the period.

The figures shown for the year ended 30 September 2008 are those of The Barrett's Oesophagus Foundation and have been included for comparative purposes only.

The notes to the accounts on pages 9 to 14 form part of these accounts.

# BARRETT'S OESOPHAGUS CAMPAIGN

## BALANCE SHEET

Company Registration No. 6675642

As at 30 September 2009

	Notes	2009 £	2008* £
<b>Fixed assets</b>			
Tangible assets	6	<u>27,000</u>	<u>36,000</u>
<b>Current assets</b>			
Cash at bank		87,638	148,491
Debtors and prepayments	7	<u>3,677</u>	<u>-</u>
		<u>91,315</u>	<u>148,491</u>
<b>Creditors: amounts falling due within one year</b>	8	<u>34,282</u>	<u>22,902</u>
<b>Net current assets</b>		<u>57,033</u>	<u>125,589</u>
<b>Net assets</b>		<u>84,033</u>	<u>161,589</u>
<b>Represented by:</b>			
General funds		19,144	97,756
Restricted funds	9	<u>64,889</u>	<u>63,833</u>
<b>Total funds</b>		<u>84,033</u>	<u>161,589</u>

\*The 2008 figures shown are those of The Barrett's Oesophagus Foundation as at 30 September 2008 and have been included for comparative purposes only.


For the period ending 30 September 2009, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The directors have:

- confirmed that the members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476 of the Act; and
- acknowledged their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.


These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The notes to the accounts on pages 9 to 14 form part of these accounts.

Approved by the board and authorised for issue on 14 May 2010



Dr P Salmon  
Director



Mr. H A Hyman  
Director

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **NOTES TO THE ACCOUNTS**

**For the financial period ended 30 September 2009**

### **1. Principal accounting policies**

#### **Basis of accounting**

The accounts have been prepared under the historical cost convention and in accordance with the requirements of the Charities Act 1993. Accounting standards and provisions of the Statement of Recommended Practice "Accounting and Reporting by Charities" (SORP 2005) applicable to small charities have been followed in these accounts.

#### **Voluntary income**

Donations represent voluntary amounts received during the period and arise within the United Kingdom. Covenant and Gift-aid income is included gross of attributable tax recoverable.

#### **Investment income**

Interest receivable is credited to income in the period in which it is earned and is included gross of attributable tax recoverable.

#### **Expenditure**

Expenditure is provided for on the accruals basis. Direct charitable expenditure of the Registry (UKBOR) comprises principally staff costs and sundry running expenses. Management and administration of the charity comprises costs directly attributable to the management of the charity including professional, regulatory and compliance costs.

#### **Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off the cost of each asset over its estimated useful life:

- Computer equipment - 1 year
- Endoscopy equipment - 5 years

#### **Fund accounting**

General funds comprise the accumulated surplus or deficit on the statement of financial activities. They are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity. Restricted funds are funds subject to specific restricted conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts where appropriate. Designated funds are funds which have been set aside at the discretion of the trustees for specific purposes. The purpose and use of the designated unrestricted funds are set out where appropriate in the notes to the accounts.

# BARRETT'S OESOPHAGUS CAMPAIGN

## NOTES TO THE ACCOUNTS (continued)

For the financial period ended 30 September 2009

### 1. Principal accounting policies (continued)

#### Taxation

The charity is not liable to direct taxation (income tax) on its income as it falls within the various exemptions available to registered charities. The charity is not registered for value added tax (VAT) and is therefore unable to reclaim the input tax it suffers on its purchases. Expenditure in the accounts is therefore shown inclusive of VAT where appropriate.

### 2. Donations received

	General Funds £	Restricted Funds £	Period ended 30.09.2009 Total £	Year ended 30.09.2008 Total £
Trust	-	10,000	10,000	1,000
Individuals	7,102	17,615	24,717	23,555
Corporate	-	-	-	3,000
	<u>7,102</u>	<u>27,615</u>	<u>34,717</u>	<u>27,555</u>

The Royal Free Hospital Hampstead provides office accommodation on a rent free basis.

### 3. Sales

	Period ended 30.09.2009 £	Year ended 30.09.2008 £
Leaflets	-	15
Tickets	-	-
	<u>-</u>	<u>15</u>

# BARRETT'S OESOPHAGUS CAMPAIGN

## NOTES TO THE ACCOUNTS (continued)

For the financial period ended 30 September 2009

### 4. Net incoming (outgoing) resources

	Period ended 30.09.2009	Year ended 30.09.2008
	£	£
Net incoming (outgoing) resources for the year is after charging:		
Staff costs	21,345	23,156
Depreciation	9,000	9,000
Auditors remuneration (including VAT)	-	881
	<u>21,345</u>	<u>32,037</u>

Staff costs represent the cost of reimbursements made for the provision of staff by a third party. The average weekly number of such staff (excluding Trustees) during the year was 1. (2008: 1).

### 5. Grants and awards

		Grants to institutions	Grants to individuals	Total
		£	£	£
Medical Research Council	- Note (a)	17,500	-	17,500
Barrett's Support Network (Wessex)	- Note (b)	500	-	500
Twort awards	- Note (c)	-	2,000	2,000
		<u>18,000</u>	<u>2,000</u>	<u>20,000</u>

- (a) This relates to the McCord Prize (worth approximately £85,000 over 3 years) established in 2008 and awarded to Dr Rebecca Fitzgerald and her group in Cambridge to evaluate ultrathin trans-nasal endoscopes compared with conventional endoscopes in the diagnosis and management of Barrett's oesophagus.
- (b) A grant of £500 was made during the period to the Wessex branch of the Barrett's Support Network for the purposes of providing support for patients
- (c) Prizes amounting to £2,000 for research into the diagnosis and management of Barrett's oesophagus were awarded to 4 individuals during the period.

# BARRETT'S OESOPHAGUS CAMPAIGN

## NOTES TO THE ACCOUNTS (continued)

For the financial period ended 30 September 2009

### 6. Tangible fixed assets

	Computer equipment £	Endoscopy equipment £	Total £
<b>Cost</b>			
At 1 October 2008	-	-	-
Transfer from The Barrett's Oesophagus Foundation	1,244	45,000	46,244
At 30 September 2009	<u>1,244</u>	<u>45,000</u>	<u>46,244</u>
<b>Depreciation</b>			
At 1 October 2008	-	-	-
Transfer from The Barrett's Oesophagus Foundation	1,244	9,000	10,244
Charge for the period	-	9,000	9,000
At 30 September 2009	<u>1,244</u>	<u>18,000</u>	<u>19,244</u>
<b>Net book value</b>			
At 30 September 2009	<u>-</u>	<u>27,000</u>	<u>27,000</u>

### 7. Debtors and prepayments

	At 30.09.2009 £	At 30.09.2008 £
Sundry debtors	55	-
Prepayments	3,622	-
	<u>3,677</u>	<u>-</u>

### 8. Creditors: amounts falling due within one year

	At 30.09.2009 £	At 30.09.2008 £
Creditors	17,863	20,215
Accruals and deferred income	16,419	2,687
	<u>34,282</u>	<u>22,902</u>

# BARRETT'S OESOPHAGUS CAMPAIGN

## NOTES TO THE ACCOUNTS (continued)

For the financial period ended 30 September 2009

### 9. Restricted Funds

	*Balances transferred at 01.10.08 £	Incoming resources £	Resources expended £	Transfers from the General fund £	Balance at 30.09.09 £
UK Barrett's Oesophagus Registry (UKBOR)	(11,875)	10,000	(22,255)	24,130	-
Website development	(308)	-	(5,608)	5,916	-
PROBE membership / branches development	404	110	(500)	6	20
Research	241	-	-	-	241
Against administrative expenses	(676)	-	-	676	-
Fundraising consultancy	26	-	(1,714)	1,688	-
Twort Fund	-	5,535	(2,000)	3,915	7,450
McCord Oesophageal Cancer Fund	76,021	12,000	(34,208)	3,365	57,178
	<u>63,833</u>	<u>27,645</u>	<u>(66,285)</u>	<u>39,696</u>	<u>64,889</u>

\*Balances transferred from The Barrett's Oesophagus Foundation

Restricted funds relating to UKBOR comprise those funds that are specifically provided for, and expended for the purposes of the operation and management (including database management) of the Registry. Website development relates to those funds specifically donated for and expended on development of the charity's website [www .barrettscampaign.org.uk](http://www.barrettscampaign.org.uk).

In the directors' opinion, donations received in previous years which should have been ring fenced for the purposes of UKBOR may have been subsumed into general funds. However, as it is a recognised objective of the charity to secure the future of UKBOR, the directors have proposed that these donations should not be identified for the purposes of these accounts but to redesignate general funds for the purposes of UKBOR as and when it is deemed necessary in the future.

### 10. Post balance sheet events

A successful fundraising event was held at Vintners Hall, London, on 5 October 2009.

During February 2010, a demerger of the McCord Oesophageal Cancer Fund was agreed by all trustee/directors in the interests of the charity and a demerger timetable was subsequently agreed. Negotiations are currently taking place during May 2010 regarding the division of assets, to be followed by completion as soon as possible.

# **BARRETT'S OESOPHAGUS CAMPAIGN**

## **NOTES TO THE ACCOUNTS (continued)**

**For the financial period ended 30 September 2009**

### **11. Related party transactions**

During the year fees totalling £12,781 (2008: £22,277) were payable to Lawrence Graham LLP. Tim Thornton-Jones, a trustee, is a partner at Lawrence Graham LLP. Trustees are not remunerated for their services as trustees.

Trustees' expenses (2 trustees) reimbursed during the year amounted to £561 (2008: £370).

### **12. Research projects**

Research projects conducted under the auspices of the UK National Barrett's Oesophagus Registry (UKBOR) but administered on its behalf and funded by third parties are not included in the accounts of the Barrett's Oesophagus Foundation.

UKBOR was awarded a research grant of some £93,000 in 2002 to conduct a study of the natural history of Barrett's oesophagus and the influence on that of medical, endoscopic and surgical treatment.

A further £45,000 was received in December 2005. The funding which was provided by the Wexham Gastrointestinal Trust enabled a research fellow to be appointed specifically for this study over three years. At 30 September 2007, the total grant was expended and administration of the project was assumed by The Royal Free and University College Medical School.

During the period the Wexham Gastrointestinal Trust provided further funding of £10,000 reducing the amount of funds required to be transferred from General Funds and redesignated for the purposes of UKBOR.



# BARRETT'S OESOPHAGUS CAMPAIGN

## PRESENTATIONS AND PUBLICATIONS (UKBOR)

### PAPERS

Published:

1. Caygill CPJ, Reed PI, McIntyre A, Hill MJ (1998). The UK National Barrett's Oesophagus Registry: A Study Between Two Centres. *Eur J. Cancer Prev*; **7**: 161-164.
2. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Ali M, Levi S (1999). A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. *Eur J Gastroent and Hep* **11**: 1355 - 1358.
3. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999) An initial comparison of nine centres registering patients with the UK National Barrett's Oesophagus Registry (UKBOR). *Eur J. Cancer Prev*; **8**: 539-542.
4. Caygill CPJ, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, Hill MJ. (2002). Lifestyle Factors and Barrett's Oesophagus. *Amer J Gastroenterology* **97**:1328-1331.
5. Caygill CPJ, Watson A, Reed PI, Hill MJ (on behalf of the UK National Barrett's Oesophagus Registry (UKBOR) and the twenty seven participating centres)\*(2003). Characteristics and Regional Variations of Patients with Barrett's oesophagus in the UK. *Eur J Gastro Hep* **15**: 1217-1222.
6. Van Blankenstein M, Looman CWN, Johnston BJ, Caygill CPJ (2005). Age and sex distribution of the prevalence of Barrett's Esophagus found in a primary referral endoscopy center. *Amer J Gastroenterology* **100**: 568-576.
7. Ramus JR, Gatenby PAC, Caygill CPJ, Watson (2007) *Helicobacter Pylori* infection and severity of reflux-induced oesophageal disease in a cohort of patients with Columnar-Lined Oesophagus *Dig Dis Sci* **52**: 2821-2825.
8. Gatenby PAC, Caygill CPJ, Ramus JR, Charlett A, Fitzgerald R, Watson A (2007) Short Segment Columnar-Lined Oesophagus (CLO) - an underestimated cancer risk? A large cohort study of the relationship between Barrett's CLO segment length and adenocarcinoma risk. *Eur J Gastro Hep* **19**: 969-975.
9. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2007). Does the length of columnar-lined esophagus change with time? *Dis Oesophagus* **20**: 497-503
10. Ramus JR, Caygill CPJ, Gatenby PAC, Watson (2008) Current UK practice in the diagnosis and management of columnar-lined oesophagus; results of the UK National Barrett's Oesophagus Registry (UKBOR) endoscopist questionnaire. *Eur J Cancer Prev* **17**: 422-425.
11. Gatenby PAC, Caygill CPJ, Ramus JR, Fitzgerald R, Charlett A, Watson A (2008). "Barrett's Columnar-Lined Esophagus: Demographic and Lifestyle Associations and Adenocarcinoma Risk" *Digestive Diseases and Sciences* **53**: 1175-85.

12. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Watson A (2008). The Relevance of the Detection of Intestinal Metaplasia in Non-Dysplastic Columnar-Lined Oesophagus. *Scand J Gastro* **43**: 524-530
13. Gatenby PAC, Ramus JR, Caygill CPJ, Charlett A, Winslet MC, Watson A (2009). Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. *Dis oesophagus* **22**: 133-42.
14. Ramus JR, Gatenby PAC, Caygill CPJ, Winslet MC, Watson A (2009) Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia. *Eur J Gastro Hep* **21**: 636-641.
15. Wall CM, Charlett A, Caygill CPJ, Gatenby PAC, Ramus JR, Winslet M, Watson A (2009). Are Newly Diagnosed Columnar-lined Oesophagus (CLO) Patients Getting Younger? *Eur J Gastro Hep* (in press).
16. Gatenby PAC, Ramus JR, Caygill CPJ, Fitzgerald RC, Charlett A, Winslet MC, Watson A (2009). The Influence of Symptom Type and Duration on the Fate of the Metaplastic Columnar-Lined Oesophagus. *Aliment Pharmacol Ther* **29**: 1096-1105.
17. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Winslet MC, Watson A (2009). Routinely diagnosed low grade dysplasia in Barrett's oesophagus: A population-based study of natural history. *Histopathology* **54**:814-9
18. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Winslet MC, Watson A (2009). Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in a multicentre cohort. *Eur J Cancer Prev.* (in press).

### **MD Theses**

1. Gatenby PAC (2008). The Natural History of Columnar-Lined Oesophagus. University of London.
2. Ramus JR (2008). Barrett's oesophagus and its progression to adenocarcinoma. A study of patient profile. University of London

### **LETTERS**

1. Fitzgerald R, Caygill CPJ (1999). Treating upper digestive track cancers as a single entity may be misleading. *British Medical Journal (BMJ)* **318**, 1289-90.
2. Caygill CPJ, Watson A (2006) The association of body mass index with Barrett's oesophagus. *Alimt Pharmacol Ther* **23**, 1027-1028.

### **INVITED PAPERS**

1. Caygill CPJ, Reed PI, Watson A, Hill MJ, (2000). "The UK National Barrett's Oesophagus Registry (UKBOR): aims and progress. *Eur J Cancer Prev.* **10**: 97-99.
2. Caygill CPJ (2001). Barrett's Oesophagus and Oesophageal Adenocarcinoma: the Epidemiological Evidence. *Acta Endoscopica* **31**, 485-490

### **INVITED REVIEWS**

1. Reed PI, Caygill CPJ, Watson A, Fitzgerald RC, (2004). The United Kingdom Barrett's Oesophagus Registry (UKBOR) - the first six years. *Gastroenterologia Polska* **10**: 299-304.
2. Caygill CPJ, Watson A, Lao-Sirieix P, Fitzgerald RC (2004). Barrett's Oesophagus and Adenocarcinoma. *World Journal of Surgical Oncology* 2:12. (Web publication) [www.wjso.com/content/2/1/12](http://www.wjso.com/content/2/1/12).

### **REPORTS**

1. Caygill CPJ, Zaninotto G, Rugge M (2008) Barrett's Registries in Europe: Report of an International Workshop. *Eur J Cancer Prev.* **17**: 426-429

### **ABSTRACTS AND POSTERS**

Published:

1. Caygill CPJ, Reed PI, Hill MJ, Watson A (1997). The UK National Barrett's Oesophagus Registry. *Gut* **40** (suppl.1): A35.
2. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Levi S (1997). A Study of Barrett's Oesophagus Registrations From a Single Centre Over a 20 Year Period. *Gut* **41** (suppl.3): E43.
3. Caygill CPJ, Reed PI, Watson A, McIntyre A, Hill MJ (1998). The First Year of the UK National Barrett's Esophagus Registry. *Gastroenterology* **114**, A87.
4. Reed PI, Caygill CPJ, Hill MJ, Watson A (1998). The UK National Barrett's Oesophagus Registry (UKBOR): The first Two Years. *Eur. J. Surgical Oncology* **24**, 457.
5. Caygill CPJ, Reed PI, Hill MJ (1998). UK National Barrett's Oesophagus Registry: A Comparison of Nine Centres. *Digestion* **59** (suppl. 3):580.

6. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslett MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. *Gut* **44**, Suppl. 1, A45.
7. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Deru K, Watson A, Levi S (1998) UK National Barrett's Oesophagus Registry : role of obesity, tobacco and alcohol in Barrett's oesophagus. *Eur. J. Cancer Prev.* **7**, 481
8. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslett MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. *Gastroenterology* **116**, Suppl 12, A351.
9. Caygill CPJ, Jankowski J, Ali M, Reed PI, Hill MJ (1999). Expression of Bile Acid Receptors: A preliminary report. *Eur. J. Cancer Prev* **8**, 354.
10. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999). The UK National Barrett's Oesophagus Registry: a Progress Report. *Eur. J. Cancer Prev.* **8**, 354
11. Caygill CPJ, Reed PI, Johnston DA, Lopez M, Hill MJ (1999) Obesity and Barrett's oesophagus in a UK Population. 1999. *Gut* **45**, A81.
12. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett's Oesophagus Registry: An Update. *Eur. J Cancer Prev.* **9**: 456-7.
13. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett's Oesophagus Registry: An Update. *Gut* **47**, (suppl. III) A68.
14. Watson A, Caygill CP (2002). The frequency of development of adenocarcinoma in Barrett's oesophagus - implications for surveillance. *Gastroenterology* **122**: A350.
15. Van Blankenstein M, Caygill CPJ, Johnston BJ (2002). The prevalence of Barrett's oesophagus (BO) in an U.K. Centre over 15 years. *Gut* **50**, (suppl. II) A123
16. Gatenby PAC, Caygill CPJ, Charlett A, Fitzgerald R, Watson A (2003) Length of Barrett's Oesophagus Segment: Demographic Associations and Cancer Risk. *Gut* **52**: (suppl. 1) A41.
17. Gatenby PAC, Caygill CPJ, Watson A, Fitzgerald R, Charlett A (2003) Length of Barrett's Oesophagus Segment: Demographic Associations and Cancer Risk. *Gastroenterology* **124**: A638.
18. Gatenby P, Caygill C, Ramus J, Bateson M, Johnston D, Fitzgerald R, Watson A (2003) Distribution of obesity by age and gender in Barrett's oesophagus patients at two culturally different centres registering with UK National Barrett's Oesophagus Registry, *J Clin Oncology* **38**: 185 (P57). (Selected for oral presentation at plenary session)
19. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A, Fitzgerald RC (2003). Association Between Lifestyle Factors and Histology in Barrett's Oesophagus. *Gut* **52**: (suppl VI) A221.

20. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Metaplasia-Dysplasia-Adenocarcinoma Sequence in Barrett's Oesophagus (CLO) in a Large UK Series. *Gut* **53**: (suppl III) A55.
21. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the Length of the Columnar-lined Oesophagus (CLO) Change with Time. *Gut* **53**: (suppl III) A35. (Selected for plenary session).
22. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Incidence of adenocarcinoma in short and long segment columnar-lined oesophagus. *Gastroenterology* **126**: (suppl 2) A308. (awarded a distinction).
23. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the length of columnar-lined oesophagus (CLO) change with time. *Gastroenterology* **126**: (suppl 2) A177. (selected as a poster of special interest).
24. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* **17**: (suppl 1) A22
25. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* **17**: (suppl 1) A126-7
26. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* 2004:17 (suppl 1) A46-7
27. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* **17**: (suppl 1) A127.
28. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004), Change in Length of the Columnar-Lined Oesophagus (CLO) over Time and Cancer Risk. *Diseases of the Esophagus* **17**: (suppl 1) A16.
29. Gatenby PAC, Ramus JR, Caygill CPJ, Fitzgerald RC, Watson A (2004). Time course of metaplastic and dysplastic changes in columnar-lined oesophagus (CLO) and relationship to symptom onset. Accepted by UEGW Sep. 2004. *Gut* **53** (suppl VI) A99.
30. Gatenby PAC, Ramus JR, Caygill CPJ, Fitzgerald RC, Watson A (2004). Relationship of presenting symptoms to outcome in columnar-lined oesophagus (CLO). *Gut* **53** (suppl VI) A101.
31. Ramus JR, Gatenby PAC, Caygill CPJ, Fitzgerald RC, Watson A (2004). Helicobacter pylori infection and severity of oesophageal disease in a cohort of patients with Barrett's oesophagus. Accepted by UEGW for oral presentation. *Gut* **53** (suppl VI) A61.

32. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2005). Impact of treatment on Barrett's Cancer incidence. *Gut* **54** (suppl 11) A52.
33. Gatenby PAC Caygill CPJ, Ramus JR, Watson A (2005). Barrett's oesophagus treatment: effect on high grade dysplasia - oesophageal cancer incidence. *Gastroenterology* **128**, (suppl 2), S1713.
34. Gatenby PAC, Caygill CPJ, Ramus JR, Shepherd N, Watson A (2005). The significance of detection of intestinal metaplasia (IM) in columnar-lined oesophagus (CLO). *The Canadian J of Gastroenterology HOME WCOG abstracts* R0078.
35. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2005). Endoscopic surveillance intervals for columnar-lined oesophagus (CLO) in the U.K. and Impact on detection of dysplastic disease. *The Canadian J of Gastroenterology HOME WCOG abstracts* R0090.
36. Ramus JR, Caygill CPJ, Gatenby PAC and Watson A. (2006). Diagnosis and management of Barrett's oesophagus; results of the UK National Barrett's Oesophagus Registry (UKBOR) endoscopist questionnaire. *Gut* **55** (suppl 11) A104-105.
37. Wall C, Charlett A, Caygill C, Gatenby P, Ramus J, Watson A (2006). Are newly diagnosed columnar-lined oesophagus patients getting younger? *J Clin Gastroenterol* **40** (suppl 4) S207.
38. Gatenby P, Ramus J R, Caygill C P J, Watson A (2007). The Relevance of Low-grade Dysplasia in Columnar-lined Oesophagus. *Gut* **56** (suppl 11) A70.
39. Gatenby P, Ramus J R, Caygill C P J, Watson A (2007). The Outcome of Low-Grade Dysplasia in Barrett's Columnar-Lined Esophagus - A large cohort study from the UK National Barrett's Oesophagus Registry. *Gastrointestinal Endoscopy* **65**: AB133
40. Gatenby PAC; Ramus JR; Caygill CPJ; Winslet MC; Watson A (2008) No Evidence of Aspirin Chemoprotection in Barrett's Adenocarcinoma of the Esophagus? *Gastrointestinal Endoscopy* **67**: AB178-AB179
41. Caygill CPJ, Charlett A, Wall C, Bardhan KD, Royston C, Gatenby P, Ramus JR, Winslet M (2009) Blood group distribution in reflux disease, columnar-lined oesophagus and oesophageal adenocarcinoma compared with the blood donating population. *Gastroenterology* **136**: (Supple 1) A601.
42. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A, Winslet M (2009) The risk of smoking on development of dysplastic disease in patients with columnarised oesophagus. (in press)

## **NOTES**

1. Reed PI, Watson A (1996). UK National Barrett's Oesophagus Registry. *Gut*; **39**: 499-500.
2. Reed PI, Watson A (1996). UK National Barrett's Oesophagus Registry. *Eur J Cancer Prev*; **5**: 207.
3. Salmon P (2007) Barrett's Oesophagus Foundation. *Gastrointestinal Nursing*; **5**: 14-17.